Vertex Pharmaceuticals Clinical Trial Pipeline — 40 Active Studies

Phase 1: 9, Phase 2: 9, Phase 3: 19, Other: 3

Vertex Pharmaceuticals has achieved a near-monopoly in cystic fibrosis (CF) through its CFTR modulator franchise. Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) is the standard of care for approximately 90% of CF patients with at least one F508del mutation, generating over $9 billion in annual revenue. Vertex is now pursuing the remaining ~10% of CF patients with the next-generation triple combination VX-522, designed for patients whose mutations do not respond to current modulators. Beyond CF, Vertex is executing a bold expansion into adjacent rare diseases: VX-880 and CTX001/exa-cel (partnered with CRISPR Therapeutics) for sickle cell disease and beta-thalassemia, VX-147 (inaxaplin) targeting APOL1-mediated kidney disease — a condition affecting Black patients disproportionately — and suzetrigine (VX-548) for acute and neuropathic pain via selective NaV1.8 sodium channel blockade, which received FDA approval as the first new non-opioid pain mechanism in decades.

• Cystic fibrosis (CFTR modulators)
• Sickle cell disease / beta-thalassemia (gene editing)
• APOL1-mediated kidney disease (VX-147)
• Non-opioid pain (NaV1.8 inhibition)
• Alpha-1 antitrypsin deficiency (AATD)
• Type 1 diabetes (islet cell therapy)

• Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) — CF CFTR modulator
• VX-522 — next-gen CFTR triple combo for non-F508del patients
• Exa-cel (exagamglogene autotemcel) — CRISPR gene editing, SCD/beta-thalassemia
• VX-147 (inaxaplin) — APOL1 inhibitor, kidney disease
• Suzetrigine (VX-548) — NaV1.8 inhibitor, acute/neuropathic pain
• VX-880 — allogeneic islet cell therapy, Type 1 diabetes

Vertex's expansion beyond CF is the most-watched rare disease story in pharma. VX-147 could be the first APOL1-targeted therapy — a massive unmet need in a genetically defined population. Their islet cell therapy program (VX-880) is the leading signal for a functional T1D cure. Monitoring Vertex's trial registrations reveals expansion into ADPKD, AATD, and new pain indications.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Vertex Pharmaceuticals's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Vertex Pharmaceuticals may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.